• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade.

作者信息

Huang Zhiyang, Li Yingying, Zhao Hong, Zhao Bin

机构信息

Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, China.

The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, China.

出版信息

J Transl Med. 2025 Feb 4;23(1):155. doi: 10.1186/s12967-025-06170-6.

DOI:10.1186/s12967-025-06170-6
PMID:39905422
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11796223/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78bf/11796223/9aca32ab7993/12967_2025_6170_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78bf/11796223/5538fab9bc29/12967_2025_6170_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78bf/11796223/9aca32ab7993/12967_2025_6170_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78bf/11796223/5538fab9bc29/12967_2025_6170_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78bf/11796223/9aca32ab7993/12967_2025_6170_Fig2_HTML.jpg

相似文献

1
Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade.异柠檬酸脱氢酶突变表明泛癌免疫检查点阻断具有良好预后。
J Transl Med. 2025 Feb 4;23(1):155. doi: 10.1186/s12967-025-06170-6.
2
Mutation of lysine-specific demethylase 5 is associated with enhanced tumor immunity and favorable outcomes in pan-cancer immune checkpoint blockade.赖氨酸特异性去甲基化酶5的突变与泛癌免疫检查点阻断中增强的肿瘤免疫和良好预后相关。
Mol Cancer. 2024 Dec 27;23(1):281. doi: 10.1186/s12943-024-02197-3.
3
Pan-cancer analysis of mutation and its association with the efficacy of immune checkpoint blockade.癌症全基因组突变分析及其与免疫检查点阻断疗效的关联
Genes Dis. 2024 Nov 8;12(4):101450. doi: 10.1016/j.gendis.2024.101450. eCollection 2025 Jul.
4
A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.具有特定免疫特征的预测 IDH1 突变型脑胶质瘤患者预后并指导免疫检查点阻断治疗
Front Immunol. 2022 Sep 9;13:1001381. doi: 10.3389/fimmu.2022.1001381. eCollection 2022.
5
Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.编码干扰素信号传导和抗原呈递的基因中的突变模式：一项泛癌研究及其对免疫检查点抑制剂使用的启示
Genes Chromosomes Cancer. 2017 Aug;56(8):651-659. doi: 10.1002/gcc.22468. Epub 2017 May 31.
6
The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.在 WHO 分级 III 和 IV 级星形胶质细胞瘤中，TIM-3 阳性细胞的存在与异柠檬酸脱氢酶突变状态相关。
Brain Pathol. 2021 May;31(3):e12921. doi: 10.1111/bpa.12921. Epub 2021 Feb 12.
7
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.携带异柠檬酸脱氢酶1/2（IDH1/2）突变的胶质母细胞瘤临床病程短，临床预后良好。
Jpn J Clin Oncol. 2016 Jan;46(1):31-9. doi: 10.1093/jjco/hyv170. Epub 2015 Nov 24.
8
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.胆管癌中异柠檬酸脱氢酶 1 和 2 的突变。
Hum Pathol. 2012 Oct;43(10):1552-8. doi: 10.1016/j.humpath.2011.12.007. Epub 2012 Apr 12.
9
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.高肿瘤突变负担未能预测所有癌症类型的免疫检查点阻断反应。
Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15.
10
Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design.基于药效团的潜在突变型异柠檬酸脱氢酶 I/2 抑制剂的鉴定：癌症药物设计的探索途径。
Anticancer Agents Med Chem. 2023;23(8):953-966. doi: 10.2174/1871520623666221129163001.

本文引用的文献

1
Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.异柠檬酸脱氢酶突变型脑胶质瘤免疫微环境及免疫治疗的研究进展
Front Immunol. 2022 Jun 13;13:914618. doi: 10.3389/fimmu.2022.914618. eCollection 2022.
2
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.在表达 IDH1R132H 的胶质瘤的新型 HLA-A2/HLA-DR1 转基因小鼠模型中，D-2HG 的抑制导致促炎基因特征上调。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004644.
3
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.
突变 IDH 抑制 IFNγ-TET2 信号通路促进胆管癌的免疫逃逸和肿瘤维持。
Cancer Discov. 2022 Mar 1;12(3):812-835. doi: 10.1158/2159-8290.CD-21-1077.
4
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌（ClarIDHy）：一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
5
Mechanisms and therapeutic implications of hypermutation in gliomas.胶质母细胞瘤中突变的机制及治疗意义。
Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15.